Involving Capsular Polysaccharide Of Bacterium (e.g., Polyribosyl Ribitol Phosphate (prp), Etc.) Patents (Class 424/831)
-
Patent number: 8974799Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerizing the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidizing the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidized saccharide residue; and (c) coupling the oxidized saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.Type: GrantFiled: September 30, 2010Date of Patent: March 10, 2015Assignee: Novartis AGInventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
-
Patent number: 8933218Abstract: The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.Type: GrantFiled: March 29, 2007Date of Patent: January 13, 2015Assignee: GlaxoSmithKline Biologicals s.a.Inventors: Ralph Leon Biemans, Pierre Duvivier, Tomas Maira-Litran
-
Patent number: 8926985Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.Type: GrantFiled: November 5, 2009Date of Patent: January 6, 2015Assignee: GlaxoSmithKline Biologicals S AInventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
-
Patent number: 8889152Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.Type: GrantFiled: January 9, 2009Date of Patent: November 18, 2014Assignee: Novartis AGInventor: Paolo Costantino
-
Patent number: 8858955Abstract: The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.Type: GrantFiled: January 2, 2008Date of Patent: October 14, 2014Assignee: GlaxoSmithKline Biologicals s.a.Inventors: Ralph Leon Biemans, Pierre Duvivier
-
Patent number: 8852606Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.Type: GrantFiled: January 14, 2009Date of Patent: October 7, 2014Assignee: Novartis AGInventor: Paolo Costantino
-
Patent number: 8753651Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from the serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.Type: GrantFiled: June 20, 2002Date of Patent: June 17, 2014Assignee: Novartis AGInventor: Paolo Costantino
-
Patent number: 8703148Abstract: The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising PNAG and Type 5 and/or 8 capsular polysaccharides are also described.Type: GrantFiled: March 29, 2007Date of Patent: April 22, 2014Assignee: GlaxoSmithKline Biologicals S.AInventors: Ralph Leon Biemans, Philippe Denoel, Pierre Duvivier, Tomas Maira-Litran, Jan Poolman
-
Patent number: 8007815Abstract: Combination vaccines for treating or preventing Neisseria meningitidis infection are described. The vaccines include Neisseria meningitidis serogroup B proteoliposomic vesicles and Neissera meningitidis serogroup C conjugated oligosaccharides.Type: GrantFiled: May 28, 1999Date of Patent: August 30, 2011Assignees: Novartis AG, Statens Institutt for FolkehelseInventors: Dan M. Granoff, Howard Raff, Ingeborg S. Aaberge, Bjorn Haneberg, Johan Holst
-
Patent number: 8003112Abstract: This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.Type: GrantFiled: April 16, 2009Date of Patent: August 23, 2011Assignees: Howard University, The United States of America as represented by the Secretary, Department of Health and Human Services; National Institutes of Health, Office of Technology TransferInventors: Stanley Shih-Peng Tai, Che-Hung Robert Lee
-
Patent number: 7858101Abstract: Modified streptococcal polysaccharides and methods of using the modified polysaccharides are provided herein.Type: GrantFiled: November 1, 2005Date of Patent: December 28, 2010Assignee: The Brigham and Women's Hospital, Inc.Inventors: Dennis L. Kasper, Hilde-Kari Guttormsen
-
Patent number: 7659090Abstract: The present invention provides improved methods for the reduction or removal of protein impurities from a complex cellular Streptococcus pneumoniae lysate or centrate comprising serotype 3 polysaccharides involving steps relating to post-lysis heating or pH adjustment. In certain methods, the lysate is heated for a time and at a temperature sufficient to denature proteins present in the lysate and cause their aggregation and precipitation. In one embodiment, the lysate is heated to at least 60° C. for at least 30 minutes to cause protein aggregation and precipitation, more particularly about 60° C. to about 70° C. for about 30 to about 50 minutes, and even more particularly about 65° C. for about 40 minutes. In other methods, the pH of the lysate or centrate is increased to at least 8.0 to improve filterability, more particularly about 8.0 to 8.4, and even more particularly about 8.2.Type: GrantFiled: October 9, 2007Date of Patent: February 9, 2010Assignee: Wyeth LLCInventors: Brian Douglas Bahler, Erik Heller Hughes, Tsu-shun Lee
-
Patent number: 7635483Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.Type: GrantFiled: August 10, 2004Date of Patent: December 22, 2009Assignee: Regents of the University of MinnesotaInventors: Paul Patrick Cleary, Deborah K. Stafslien
-
Patent number: 7332173Abstract: This invention provides a novel immunogenic composition and vaccine, processes for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositions include group A streptococcal polysaccharide covalently linked to protein or liposomes to form immunogenic conjugates. The method of immunization for this invention comprises administering to an individual an immunogenic amount of group A polysaccharide. The group A polysaccharide may be administered as a vaccine either on its own, conjugated to proteins or conjugated to liposomes. Additionally, the group A polysaccharides may be associated with an adjuvant. This invention is particularly useful for providing both active and passive immunogenic protection for those populations most at risk of contracting group A Streptococcal infections and disease namely adults, pregnant women and in particular infants and children.Type: GrantFiled: March 21, 2005Date of Patent: February 19, 2008Assignees: The Rockefeller University, Baxter International Inc.Inventors: Milan S. Blake, John B. Zabriskie, Joseph Y. Tai, Francis Michon
-
Patent number: 7291343Abstract: A majority of E. faecalis and E. faecium clinical isolates fall into two groups and three groups, respectively. Distinct antigens are associate with each of the five groups. The Enterococcus antigens are readily obtained from strains of E. faecalis and E. faecium, and can elicit production of protective antibodies. Accordingly, the antigens are useful for vaccines which protect against infection by clinically significant (pathogenic) Enterococcus isolates. The antigens and antibodies generated to the antigens are also useful in diagnostic assays.Type: GrantFiled: June 28, 2004Date of Patent: November 6, 2007Assignee: Nabi BiopharmaceuticalsInventors: Ali Ibrahim Fattom, Ramesh K. Sood, Sara E. Shepherd
-
Patent number: 7252828Abstract: The invention relates to compositions of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a vaccine for inducing active immunity to infections caused by Staphylococcus aureus, S. epidermidis, other related coagulase-negative staphylococci and organisms carrying the ica (intracellular adhesin) locus, and to the use of antibodies directed to PS/A for inducing passive immunity to the same class of infections.Type: GrantFiled: January 26, 2001Date of Patent: August 7, 2007Assignee: The Brigham and Women's Hospital, Inc.Inventors: Gerald B. Pier, Julia Y. Wang, David McKenney
-
Patent number: 7169392Abstract: The present invention pertains generally to novel Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.Type: GrantFiled: August 19, 2003Date of Patent: January 30, 2007Assignee: Chiron SrlInventor: Robert Seid
-
Patent number: 7101562Abstract: The present invention provides glucan-based compositions and methods for stimulating an immune response against mutans streptococci components and vaccines and methods for the treatment and prevention of dental caries. In a preferred embodiment, a glucan polymer, preferably WSG, is covalently bound to one or more T cell-dependent antigens to form a conjugate vaccine. The T cell-dependent antigen preferably contains epitopes of one or more mutans streptococcal proteins, such as a glucosyltransferase. Moreover, one or more moieties, including haptens, may be conjugated to the glucan-T cell-dependent composition. In a preferred embodiment, these moieties are peptides which contain immunogenic epitopes corresponding to components of a mutans streptococcus.Type: GrantFiled: May 1, 2000Date of Patent: September 5, 2006Assignees: The Forsyth Institute, Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Andrew Lees, Martin A. Taubman, Daniel J. Smith
-
Patent number: 7005129Abstract: A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.Type: GrantFiled: November 27, 1996Date of Patent: February 28, 2006Assignees: University of Iowa Research Foundation, The Regents of the University of CaliforniaInventors: Michael A. Apicella, Melvin G. Sunshine, Na-Gyong Lee, Bradford W. Gibson, Rasappa Arumugham
-
Patent number: 6984381Abstract: A novel vaccine for immunizing animals against Staphylococcus aureus-induced mastitis is disclosed. The vaccine is comprised of whole killed cells of S. aureus in a dosage effective to immunize an animal against the organism, in combination with a pharmaceutically acceptable carrier.Type: GrantFiled: July 5, 2002Date of Patent: January 10, 2006Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Albert Guidry, Celia O'Brien
-
Patent number: 6855321Abstract: The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines arm particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.Type: GrantFiled: April 27, 1999Date of Patent: February 15, 2005Assignee: Chiron S.r.l.Inventors: Rino Rappuoli, Guido Grandi
-
Patent number: 6764686Abstract: This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector.Type: GrantFiled: July 21, 1998Date of Patent: July 20, 2004Assignee: Baxter International Inc.Inventors: Conceicao Minetti, Francis Michon, Jeffrey K. Pullen, Mary Ellen Polvino-Bodnar, Shu-Mei Liang, Joseph Y. Tai
-
Patent number: 6638513Abstract: The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.Type: GrantFiled: August 7, 1997Date of Patent: October 28, 2003Assignee: Chiron S.r.l.Inventor: Robert Seid
-
Patent number: 6602508Abstract: The process for depolymerizing Group B Types II and III streptococcal polysaccharide is disclosed which results in polysaccharide fragments having a reducing end suitable for conjugating to protein. Conjugate molecules, vaccines and their use to immunize mammals including humans are also disclosed.Type: GrantFiled: May 18, 2001Date of Patent: August 5, 2003Assignee: Baxter International Inc.Inventors: Francis Michon, Catherine Uitz, Joseph Y. Tai
-
Patent number: 6596283Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.Type: GrantFiled: July 20, 2001Date of Patent: July 22, 2003Assignee: National Research Council of CanadaInventors: Harold J. Jennings, Robert Pon, Michele Lussier, Francis Michon
-
Patent number: 6423320Abstract: A polysaccharide and fragments thereof derived from Klebsiella oxytoca or Klebsiella pneumonia inhibit the IgE antibody production and response and, therefore, are useful in the prophylaxis and/or treatment of type I allergy-related diseases.Type: GrantFiled: August 19, 1998Date of Patent: July 23, 2002Assignee: Tayca CorporationInventors: Hitoshi Oomori, Yoichi Ooiso, Ryosuke Sugihara
-
Patent number: 6372222Abstract: The process for depolymerizing Group B Types II and III Streptococcal Polysaccharide is disclosed which results in polysaccharide fragments having a reducing end suitable for conjugating to protein. Conjugate molecules, vaccines and their use to immunize mammals including humans are also disclosed.Type: GrantFiled: February 18, 1998Date of Patent: April 16, 2002Assignee: Baxter International Inc.Inventors: Francis Michon, Catherine Uitz, Joseph Y. Tai
-
Patent number: 6333036Abstract: Vaccine compositions are disclosed which comprise at least one antigen formed by the capsular polysaccharide of Haemophilus influenzae type b or high molecular weight polyribosylribitol phosphate coupled to tetanus anatoxin.Type: GrantFiled: December 30, 1997Date of Patent: December 25, 2001Assignee: Pasteur Merieux Serums, et Vaccins S.A.Inventors: Francois Arminjon, Jean-René Cartier
-
Patent number: 6280738Abstract: A-X202X203X204X205X206X207X208X209X210X211X212X213-B, wherein A represents amino acid residues 38-201 of SEQ ID NO: 2, B represents a sequence starting from amino acid 214 of SEQ ID NO: 2 and terminating at an amino acid between residues 1131 and 1164, inclusive, of SEQ ID NO: 2, and X202 through X213 are each selected independently from Ala, Val, Leu, Ile, Pro, Met, Phe, Trp, a bond, or a wild-type amino acid as found at a corresponding position of residues 202-213 of SEQ ID NO: 2, with the proviso that at least one of X202 through X213, inclusive, is other than the wild type amino acid found at the corresponding position of SEQ ID NO: 2. The LPXTG motif, as found in the native protein at amino acid residues corresponding to residues 1132-1136 of SEQ ID NO: 2, may be deleted in the sequence of the mutant C&bgr; protein.Type: GrantFiled: September 5, 1997Date of Patent: August 28, 2001Assignee: Baxter International Inc.Inventors: Joseph Y. Tai, Milan S Blake
-
Patent number: 6251401Abstract: A combined vaccine for bacterial meningitis comprises Hib and MenC oligosaccharide conjugates.Type: GrantFiled: May 1, 1997Date of Patent: June 26, 2001Assignee: Chiron S.p.A.Inventors: Costante Ceccarini, Paolo Costantino, Sandro D'Ascenzi, Francesco Norelli, Aldo Giannozzi
-
Patent number: 6190669Abstract: Attenuated Salmonella mutants which constitutively express the Vi antigen are disclosed, as well as vaccines against typhoid fever containing the same, live vector vaccines containing the same, and DNA-mediated vaccines containing the same.Type: GrantFiled: May 13, 1998Date of Patent: February 20, 2001Assignee: University of Maryland, BaltimoreInventors: Fernando R. Noriega, Marcelo B. Sztein, Myron M. Levine
-
Patent number: 6177085Abstract: Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a Streptococcus strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from Streptococcus pneumoniae are linked to an outer membrane protein of a Haemophilus influenzae strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than Streptococcus also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the Streptococcus strain and preferably also the Haemophilus strain.Type: GrantFiled: June 6, 1995Date of Patent: January 23, 2001Assignee: Connaught Laboratories LimitedInventors: Yan-ping Yang, Ali Kandil, Lucy Gisonni, Raafat Emil Fahmy Fahim, Michel Henri Klein
-
Patent number: 6045805Abstract: An oligosaccharide derived from an antigen polysaccharide obtained from a pathogenic agent, a method for its preparation, and its use particularly as a vaccinal agent. The oligosaccharide is prepared by oxidation-reduction depolymerization reaction.Type: GrantFiled: June 7, 1995Date of Patent: April 4, 2000Assignee: Pasteur Merieux Serums et VaccinesInventor: Monique Moreau
-
Patent number: 6007818Abstract: An oligoside derived from an antigen polyoside obtained from a pathogenic agent, a method for its preparation, and its use particularly as a vaccinal agent. The oligoside is prepared by oxidation-reduction depolymerisation reaction.Type: GrantFiled: June 7, 1995Date of Patent: December 28, 1999Assignee: Pasteur Merieux Serums Et VaccinesInventor: Monique Moreau
-
Patent number: 5968548Abstract: Liposome-encapsulated quinolones and specifically liposome-encapsulated ciprofloxacin dramatically enhances macrophage functions, induces NO production and augments the production of cytokines, rendering the composition an immunoprophylactic and immunotherapeutic agent with unique clinical potential. Liposome-encapsulated ciprofloxacin and other quinolones could be extremely useful in antimicrobial, anticancer and AIDS therapies. In such cases, the immunological status of the patient is often compromised or suppressed, making them susceptible to microbial infections and to the development of tumor growth. Selective augmentation of cellular immunity by activation of the microbicidal and tumoricidal activities of macrophages, induction of NO and cytokine production could be of primary importance to such patients in terms of protecting them against microbial infections and inducing their cellular host defense to tumor cells.Type: GrantFiled: April 16, 1997Date of Patent: October 19, 1999Assignee: Minister of National Defence of Her Majesty's Canadian GovernmentInventors: Jonathan P. Wong, Edward G. Saravolac, Les P. Nagata
-
Patent number: 5770213Abstract: The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of non-typable Haemophilus influenzae infection.Type: GrantFiled: May 5, 1994Date of Patent: June 23, 1998Assignee: American Cyanamid CompanyInventor: Gary W. Zlotnick
-
Patent number: 5700787Abstract: Methods and products for protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. Methods for forming immunomodulators and pharmaceutical compositions relating thereto also are provided. The products useful in the invention are polysaccharides including a repeat unit having a positively charged free amino group and a negatively charged group. The preferred polysaccharide is B. fragilis capsular polysaccharide A.Type: GrantFiled: July 14, 1995Date of Patent: December 23, 1997Assignee: Brigham & Women's Hospital, Inc.Inventors: Arthur O. Tzianabos, Andrew B. Onderdonk, Dennis L. Kasper
-
Patent number: 5679654Abstract: Methods and products for protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. Methods for forming immunomodulators and pharmaceutical compositions relating thereto also are provided. The products useful in the invention are polysaccharides including a repeat unit having a positively charged free amino group and a negatively charged group. The preferred polysaccharide is B. fragilis capsular polysaccharide A.Type: GrantFiled: September 2, 1994Date of Patent: October 21, 1997Assignee: Brigham & Women's Hospital, Inc.Inventors: Arthur O. Tzianabos, Andrew B. Onderdonk, Dennis L. Kasper
-
Patent number: 5445817Abstract: A medically important and useful conjugate comprising pertussis toxin (PT), or another antigen having similar physico-chemical properties, as the carrier protein component, coupled to a neutral or non-charged saccharide, particularly, the capsular polysaccharide of Streptococcus pneumoniae type 14 (Pn14), for use as an effective, non-toxic, and highly immunogenic vaccine is described. The invention is directed to a novel synthetic scheme wherein PT and like proteins, and a derivative of Pn14, and the like, were coupled at acidic pH via carbodiimide-mediated condensation to produce an immunogenic conjugate. The coupling procedure yielded a Pn14-PT conjugate in which the PT component was rendered non-toxic and both the PT and Pn14 components were immunogenic, as determined by the production of protective levels of both type-specific and neutralizing antibodies in mammals.Type: GrantFiled: August 21, 1992Date of Patent: August 29, 1995Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rachel Schneerson, Lily Levi, John B. Robbins
-
Patent number: 5371197Abstract: A conjugate immunogen, having polysaccharide moieties derived from bacterial sources, provides a multivalent vaccine with a low protein to polysaccharide ratio. The vaccine reduces complications associated with injection of protein immunogens due to pyrogenic responses, such as swelling and pain, and is particularly suitable for administration to infants.Type: GrantFiled: September 24, 1991Date of Patent: December 6, 1994Assignee: Merck & Co., Inc.Inventors: Stephen Marburg, Richard L. Tolman
-
Patent number: 5360897Abstract: An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having at least one reducing group and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also relates to methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for inducing active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate. In a preferred embodiment, the capsular polymer fragment prior to conjugation has at least one aldehyde group at each end of the fragment. The final conjugate made with such capsular polymers has a lattice or network structure, and provides extremely high levels of anti-capsular polymer antibodies in infants.Type: GrantFiled: January 9, 1992Date of Patent: November 1, 1994Assignee: The University of RochesterInventors: Porter W. Anderson, Ronald J. Eby
-
Patent number: 5334379Abstract: This invention pertains to immunogenic conjugates comprising a carbohydrate containing antigen or other antigen bound to or genetically fused with a cytokine, lymphokine, hormone or growth factor having immunomodulating activity, wherein the cytokine, lymphokine, hormone or growth factor is capable of modifying immunogenicity of the carbohydrate containing antigen. The cytokine or lymphokine can be an interleukin or an interferon. The immunogenic conjugate can be used in vaccine and co-vaccine formulations.Type: GrantFiled: July 16, 1990Date of Patent: August 2, 1994Assignee: American Cyanamid CompanyInventors: Subramonia Pillai, Ronald Eby
-
Patent number: RE37741Abstract: The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of non-typable Haemophilus influenzae infection.Type: GrantFiled: June 21, 2000Date of Patent: June 11, 2002Assignee: American Cyanamid CompanyInventor: Gary W. Zlotnick